Literature DB >> 25892859

Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.

Letiția Adela Maria Streba1, Cristin Constantin Vere1, Ion Rogoveanu1, Costin Teodor Streba1.   

Abstract

Non-alcoholic liver disease (NAFLD) defines liver abnormalities ranging from simple steatosis to nonalcoholic steatohepatitis with or without cirrhosis development, occurring in the absence of significant alcohol consumption, use of teratogenic medication, or hereditary disorders. The association between NAFLD and metabolic syndrome is well documented and widely recognized. Obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia are the most common metabolic risk factors associated with NAFLD. Among the components of metabolic syndrome, current evidence strongly indicates obesity and diabetes as hepatocellular carcinoma (HCC) risk factors. There is also growing evidence that suggests an increased risk of HCC in NAFLD patients, even surpassing other etiologies in some high-income countries. Epidemiologic data demonstrate a parallel rise in prevalence of obesity, diabetes, NAFLD, and HCC. As obesity and its related diseases have steadily afflicted larger populations, HCC incidence is expected to increase in the future. Pathophysiologic mechanisms that underlie NAFLD development and subsequent progression to nonalcoholic steatohepatitis and cirrhosis (insulin resistance and hyperinsulinemia, oxidative stress, hepatic stellate cell activation, cytokine/adipocytokine signaling pathways, and genetic and environmental factors) appear to play a significant role in the development of NAFLD-related HCC. However, a comprehensive view of molecular mechanisms linking obesity, T2DM, and NAFLD-related HCC, as well as the exact sequence of molecular events, is still not understood in its entirety. Good-quality data are still necessary, and efforts should continue towards better understanding the underlying carcinogenic mechanisms of NAFLD-related HCC. In this paper, we aimed to centralize the most important links supporting these relationships, focusing on obesity, T2DM, and NAFLD-related HCC, as well as point out the major gaps in knowledge regarding the underlying molecular mechanisms behind them.

Entities:  

Keywords:  Diabetes mellitus; Hepatocellular carcinoma; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity

Mesh:

Year:  2015        PMID: 25892859      PMCID: PMC4394070          DOI: 10.3748/wjg.v21.i14.4103

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  93 in total

Review 1.  Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Authors:  K Breuhahn; T Longerich; P Schirmacher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 3.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

Review 4.  Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies.

Authors:  Yi Chen; Xiaolin Wang; Jianhua Wang; Zhiping Yan; Jianjun Luo
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

Review 5.  What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

Review 6.  Obesity and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population.

Authors:  Keitaro Tanaka; Ichiro Tsuji; Akiko Tamakoshi; Keitaro Matsuo; Hidemi Ito; Kenji Wakai; Chisato Nagata; Tetsuya Mizoue; Shizuka Sasazuki; Manami Inoue; Shoichiro Tsugane
Journal:  Jpn J Clin Oncol       Date:  2012-01-12       Impact factor: 3.019

Review 7.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

8.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

9.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

Review 10.  Targeting insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Jennifer Wu; Andrew X Zhu
Journal:  J Hematol Oncol       Date:  2011-07-05       Impact factor: 17.388

View more
  47 in total

1.  Sonographic Features of the Liver Among Females with Type 2 Diabetes.

Authors:  Bárbara L Riestra-Candelaria; Loida A González-Rodríguez; Wilma Rodriguez-Mojica; Luis E Vázquez-Quiñones; Juan Carlos Jorge
Journal:  J Diagn Med Sonogr       Date:  2019-03-08

Review 2.  HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.

Authors:  Thomas J Vogl; Tatjana Gruber-Rouh
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

3.  Pediatric Fatty Liver Disease.

Authors:  Ajay Jain
Journal:  Mo Med       Date:  2019 Mar-Apr

Review 4.  Dysregulated fatty acid metabolism in hepatocellular carcinoma.

Authors:  Mingda Wang; Jun Han; Hao Xing; Han Zhang; Zhenli Li; Lei Liang; Chao Li; Shuyang Dai; Mengchao Wu; Feng Shen; Tian Yang
Journal:  Hepat Oncol       Date:  2017-06-30

Review 5.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

Review 6.  New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.

Authors:  Natalia Pydyn; Katarzyna Miękus; Jolanta Jura; Jerzy Kotlinowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

7.  Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity.

Authors:  John D Clarke; Anika Dzierlenga; Tarana Arman; Erica Toth; Hui Li; Katherine D Lynch; Dan-Dan Tian; Michael Goedken; Mary F Paine; Nathan Cherrington
Journal:  Toxicon       Date:  2019-03-05       Impact factor: 3.033

8.  Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.

Authors:  Ali Zarrinpar; Claire M Faltermeier; Vatche G Agopian; Bita V Naini; Michael P Harlander-Locke; Fady M Kaldas; Douglas G Farmer; Ronald W Busuttil
Journal:  Liver Int       Date:  2018-12-02       Impact factor: 5.828

9.  Therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced fatty liver disease, fibrosis and inflammation in rabbit.

Authors:  Pao-Yuan Lin; Chih-Hung Chen; Christopher Glenn Wallace; Kuan-Hung Chen; Chia-Lo Chang; Hong-Hwa Chen; Pei-Hsun Sung; Kun-Chen Lin; Sheung-Fat Ko; Cheuk-Kwan Sun; Hsueh-Wen Chang; Pei-Lin Shao; Mel S Lee; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 10.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.